These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31276039)

  • 1. The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor-α inhibitor.
    Suzuki T; Mizoshita T; Tanida S; Sugimura N; Katano T; Nishie H; Kataoka H
    JGH Open; 2019 Jun; 3(3):217-223. PubMed ID: 31276039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study.
    Matsumoto S; Kawamura H; Nishikawa T; Sagihara N; Miyatani H; Mashima H
    Clin Exp Gastroenterol; 2017; 10():249-258. PubMed ID: 29026326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis.
    Numa K; Kakimoto K; Tanaka Y; Mizuta N; Kinoshita N; Nakazawa K; Koshiba R; Hirata Y; Ota K; Miyazaki T; Nakamura S; Higuchi K; Nishikawa H
    J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study.
    Yamamoto T; Shimoyama T; Umegae S; Matsumoto K
    Aliment Pharmacol Ther; 2016 Mar; 43(6):705-16. PubMed ID: 26762838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study.
    Oshima N; Hiraoka S; Hayashi R; Takahashi S; Ishii M; Hashimoto S; Yashima K; Igawa S; Inokuchi T; Ueno Y; Inaba T; Matsumoto H; Kawashima K; Takami T; Isomoto H; Shiotani A; Tanaka S; Ishihara S
    Inflamm Bowel Dis; 2024 Jul; 30(7):1087-1093. PubMed ID: 37598298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
    Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
    Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients.
    Kitayama M; Akazawa Y; Yoshikawa D; Higashi S; Morisaki T; Oda H; Ikeda M; Nakashima Y; Tabuchi M; Hashiguchi K; Matsushima K; Yamaguchi N; Kondo H; Nakao K; Takeshima F
    Sci Rep; 2020 Jul; 10(1):12546. PubMed ID: 32719413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-Term and Long-Term Outcomes of Infliximab and Tacrolimus Treatment for Moderate to Severe Ulcerative Colitis: Retrospective Observational Study.
    Otsuka T; Ooi M; Tobimatsu K; Wakahara C; Watanabe D; Adachi S; Yasutomi E; Yamairi H; Ku Y; Yoshida M; Hoshi N; Kodama Y
    Kobe J Med Sci; 2018 Dec; 64(4):E140-E148. PubMed ID: 30728340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis.
    Endo K; Onodera M; Shiga H; Kuroha M; Kimura T; Hiramoto K; Kakuta Y; Kinouchi Y; Shimosegawa T
    Gastroenterol Res Pract; 2016; 2016():3162595. PubMed ID: 26904108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis.
    Lv R; Qiao W; Wu Z; Wang Y; Dai S; Liu Q; Zheng X
    PLoS One; 2014; 9(1):e86692. PubMed ID: 24475168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus for the Treatment of Ulcerative Colitis.
    Matsuoka K; Saito E; Fujii T; Takenaka K; Kimura M; Nagahori M; Ohtsuka K; Watanabe M
    Intest Res; 2015 Jul; 13(3):219-26. PubMed ID: 26130996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiopurine naivety at tacrolimus induction is a predictor of long-term remission in patients with intractable ulcerative colitis who responded to tacrolimus.
    Takatsu N; Hisabe T; Kishi M; Takeda T; Yasukawa S; Koga A; Kinjo K; Hirai F; Ueki T; Yao K
    J Gastroenterol Hepatol; 2023 Jan; 38(1):52-60. PubMed ID: 36128954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis.
    Nishio M; Ishii Y; Hashimoto Y; Otake H; Ogashiwa T; Tsuda S; Yasuhara H; Saigusa Y; Kimura H; Maeda S; Kunisaki R
    Scand J Gastroenterol; 2018; 53(10-11):1236-1244. PubMed ID: 30353757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis.
    Takeuchi K; Shimoyama T; Yamamoto T
    Dig Dis; 2018; 36(2):106-112. PubMed ID: 29050007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective investigation of tacrolimus combined with an anti-tumor necrosis factorα antibody as remission induction therapy for refractory ulcerative colitis: Efficacy, safety, and relapse rate.
    Ito A; Omori T; Nakamura S; Tokushige K
    JGH Open; 2019 Dec; 3(6):525-531. PubMed ID: 31832554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis.
    Yamagami H; Nishida Y; Nagami Y; Hosomi S; Yukawa T; Otani K; Tanaka F; Taira K; Kamata N; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y
    Rom J Intern Med; 2017 Sep; 55(3):151-157. PubMed ID: 28222041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis.
    Yamamoto S; Nakase H; Matsuura M; Masuda S; Inui K; Chiba T
    J Clin Gastroenterol; 2011 Jul; 45(6):526-30. PubMed ID: 21336140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral tacrolimus as maintenance therapy for refractory ulcerative colitis--an analysis of outcomes in two London tertiary centres.
    Landy J; Wahed M; Peake ST; Hussein M; Ng SC; Lindsay JO; Hart AL
    J Crohns Colitis; 2013 Dec; 7(11):e516-21. PubMed ID: 23623737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study.
    Minami N; Yoshino T; Matsuura M; Koshikawa Y; Yamada S; Toyonaga T; Madian A; Honzawa Y; Nakase H
    BMJ Open Gastroenterol; 2015; 2(1):e000021. PubMed ID: 26462273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis.
    Hoffmann P; Wehling C; Krisam J; Pfeiffenberger J; Belling N; Gauss A
    World J Gastroenterol; 2019 Apr; 25(13):1603-1617. PubMed ID: 30983820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.